XENE Dec 2024 55.000 call
| Previous close | 7.04 |
| Open | 7.04 |
| Bid | 1.65 |
| Ask | 6.40 |
| Strike | 55.00 |
| Expiry date | 2024-12-20 |
| Day's range | 7.04 - 7.04 |
| Contract range | N/A |
| Volume | |
| Open interest | 25 |
GlobeNewswireXenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
VANCOUVER, British Columbia, June 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will present at the Goldman Sachs 45th Annual Global Healthcare Conference taking place June 10-13, 2024 in Miami, FL. Fireside Chat Presentation Details: Date:Wednesday, June 12, 2024Time:4:00 pm Eastern TimeWebcast:Register herePresenters:Ian Mortimer, President and Chief Executive OfficerChris Von Seggern, C
Simply Wall St.Shareholders Will Probably Not Have Any Issues With Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) CEO Compensation
Key Insights Xenon Pharmaceuticals to hold its Annual General Meeting on 4th of June Total pay for CEO Ian Mortimer...
- GlobeNewswire
Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting
VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced data presentations highlighting azetukalner (XEN1101) clinical data in major depressive disorder (MDD) at the American Society of Clinical Psychopharmacology (ASCP) 2024 Annual Meeting in Miami, FL. Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer, stated, “We are pleased to present these data from our Phase 2 proof-of-
